We are live on
!
Find out more
NCM
Niemann Capital Management Portfolio holdings
AUM
$788K
1-Year Est. Return
23.27%
This Fund
S&P 500
This Quarter
Est. Return
+5.7%
1 Year Est. Return
+23.27%
3 Year Est. Return
+102.79%
5 Year Est. Return
+328.66%
10 Year Est. Return
–
AUM
$121M
AUM Growth
–
Cap. Flow
+$121M
Cap. Flow
% of AUM
99.4%
Top 10 Holdings %
Top 10 Hldgs %
86.71%
Holding
16
New
16
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Invesco Pharmaceuticals ETF
PJP
|
+$13.9M |
| 2 |
iShares Biotechnology ETF
IBB
|
+$13.8M |
| 3 |
VanEck Biotech ETF
BBH
|
+$12.9M |
| 4 |
State Street SPDR S&P Insurance ETF
KIE
|
+$12.2M |
| 5 |
RWW
Invesco S&P Financials Revenue ETF
RWW
|
+$10.2M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|
Similar funds
RC
GBA
AIDCT
VAIA
SAM
FPC
GFWEX
HAM
Niemann Capital Management's Q2 2013 Portfolio in Review
Q2 2013 is the first quarter with a 13F filing on record for Niemann Capital Management, which disclosed 16 positions worth $121M. Its ten largest holdings account for 87% of the portfolio.
Its largest position is Invesco Pharmaceuticals ETF: 334,023 shares worth $14.1M.
- Niemann Capital Management's largest Q2 2013 buy was Invesco Pharmaceuticals ETF: 334,023 shares worth $14.1M.
- Niemann Capital Management's ten largest holdings make up 87% of its $121M portfolio in Q2 2013.
- Niemann Capital Management disclosed 16 positions in Q2 2013, its first 13F filing on record.
Based on Niemann Capital Management's 13F filing for Q2 2013, filed 7 Aug 2013.